In vivo and in vitro pharmacodynamic experiments are an important basis for CAR-T clinical transformation and the key to ensuring the clinical effectiveness and safety of CAR-T. iCarTab is committed to the development of tumor immunotherapy technology and has established a complete set of CAR -T in vitro and in vivo pharmacodynamic experiment platform. Since 2015, we have provided global customers with more than 100 projects of chimeric antigen receptor T cell verification services, and some CAR-T products have officially entered the clinical trial stage. On this basis, we can provide you with the most professional CAR-T service.
Strict laboratory data storage plan, experimental data can be traced
In addition to conventional cell lines, we can construct new recombinant cell lines according to project requirements to ensure the smooth progress of the test project in all aspects
Mouse tumor formation experience of multiple cell lines, covering a variety of solid tumors and hematomas, to meet the needs of different projects
CD19 is currently the most mature target for CAR-T clinical transformation. The following figure shows part of the in vivo and in vitro pharmacodynamic experimental data of iCarTab-targeted CD19 CAR-T.